India, March 21 -- The company said the decision to start advanced injectable therapy is often delayed in many patients due to cost and complexity. With GLIPIQ, Glenmark aims to improve affordability and enable earlier treatment initiation across a broader patient population. GLIPIQ has been approved by the Central Drugs Standard Control Organization (CDSCO) following a multicentre, randomised, comparative, active-controlled, open-label Phase III clinical study conducted in India. The study demonstrated favourable efficacy and safety outcomes in Indian patients with Type 2 diabetes.

The drug is available in both vial and pre-filled pen formulations. The vial-based version, supported by dose-specific syringes, is designed to allow flexibl...